Leica Biosystems, ACD co-market RNAscope LS ISH assays and BOND RX instrument

Leica Biosystems and Advanced Cell Diagnostics, Inc. (ACD) have announced the co-marketing of ACD's RNAscope® LS ISH assays with Leica Biosystems' BOND RX research staining platform. This agreement provides researchers with an integrated and fully automated ISH solution. The market-leading RNAscope LS reagent kits and ISH probes are available from ACD while the BOND RX instrument and associated reagents are supplied by Leica Biosystems.

ACD's RNAscope assays represent a major technological advance for in situ RNA detection. For the first time, robust single RNA molecule detection is available for formalin-fixed, paraffin-embedded (FFPE) tissue. Since their commercialization three years ago, these assays have been adopted across the globe by major pharma biotech companies and leading research institutions for drug discovery, translational research, and the development of clinical and companion diagnostic tests. The RNAscope LS assays are fully automated on the BOND RX platform. This open and flexible system automates staining to provide a fast, high-throughput workflow with exceptional consistency and minimal hands-on time.

"Automation is essential for pharma, biotech, translational labs and academic institutions to apply the RNA ISH technology to a wide range of biomarker analysis applications." said Dr. Yuling Luo, President and CEO of ACD. "We are very pleased to work with Leica Biosystems to expand our automated RNAscope solutions in response to the needs of our rapidly growing customer base."

Dr. David Atkins, VP Advanced Staining at Leica Biosystems added: "Leica is excited to announce the availability of ACD's RNAscope Assays fully automated on the BOND RX. This is another example of how, with its openness and flexibility, the BOND RX is providing researchers with enhanced tools to help speed-up important discoveries and improve cancer diagnostics".

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Advanced Cell Diagnostics. (2019, June 24). Leica Biosystems, ACD co-market RNAscope LS ISH assays and BOND RX instrument. News-Medical. Retrieved on April 15, 2024 from https://www.news-medical.net/news/20140813/Leica-Biosystems-ACD-co-market-RNAscope-LS-ISH-assays-and-BOND-RX-instrument.aspx.

  • MLA

    Advanced Cell Diagnostics. "Leica Biosystems, ACD co-market RNAscope LS ISH assays and BOND RX instrument". News-Medical. 15 April 2024. <https://www.news-medical.net/news/20140813/Leica-Biosystems-ACD-co-market-RNAscope-LS-ISH-assays-and-BOND-RX-instrument.aspx>.

  • Chicago

    Advanced Cell Diagnostics. "Leica Biosystems, ACD co-market RNAscope LS ISH assays and BOND RX instrument". News-Medical. https://www.news-medical.net/news/20140813/Leica-Biosystems-ACD-co-market-RNAscope-LS-ISH-assays-and-BOND-RX-instrument.aspx. (accessed April 15, 2024).

  • Harvard

    Advanced Cell Diagnostics. 2019. Leica Biosystems, ACD co-market RNAscope LS ISH assays and BOND RX instrument. News-Medical, viewed 15 April 2024, https://www.news-medical.net/news/20140813/Leica-Biosystems-ACD-co-market-RNAscope-LS-ISH-assays-and-BOND-RX-instrument.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advanced Cell Diagnostics’ in situ hybridization technology reaches two major milestones